YPYing Peng

Ying Peng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ying Peng has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of sleep duration and changes in body mass index on diabetic kidney disease: a prospective cohort study

    by Cong Liu, Jia Zhang, Xing Wei, Juan Shi, Qianhua Fang, Weiwei Zhou, Lin Sun, Zhuomeng Hu, Jie Hong, Weiqiong Gu, et al.

    Aims: To examine the associations of sleep duration and changes in BMI with the onset of diabetic kidney disease (DKD).Materials and methods: 2,959 participants with type 2 diabetes were divided into three groups based on sleep duration: short (9 h/day). Changes in BMI during follow-up were trisected into loss, stable, or gain groups. DKD was defined as either the urinary albumin/creatinine ratio (UACR) ≥ 3.39 mg/mmol or the estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m², or both. Cox regression models were used to assess hazard ratios (HRs) and 95% confidence intervals (CIs).Results: During a mean follow-up of 2.3 years, DKD occurred in 613 participants (20.7%). A J-shaped curve was observed between sleep duration and DKD. Compared to intermediate sleep duration, long sleep duration was associated with higher risks of DKD (HR 1.47; 95% CI: 1.19-1.81). In the joint analyses, compared to participants with intermediate sleep duration and stable BMI, long sleep duration with BMI gain had the highest risks of DKD (HR 2.04; 95% CI: 1.48-2.83). In contrast, short or intermediate sleep duration accompanied by decrease in BMI was associated with a reduced risk of DKD, with HRs of 0.50 (95% CI: 0.31-0.82) and 0.61 (95% CI:0.47-0.80), respectively.Conclusions: Long sleep duration is significantly associated with an increased risk of DKD, which is further amplified by obesity or BMI gain. These findings suggest that both proper sleep duration and weight control are essential to preventing DKD.


  • Open Access

    Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice

    by Minqi Xiang, Xu Qian, Luyu Han, Hui Wang, Jiqiu Wang, Weiren Liu, Yanyun Gu, Shuangshuang Yao, Jian Yang, Yifei Zhang, et al.

  • Open Access

    Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice

    by Minqi Xiang, Xu Qian, Luyu Han, Hui Wang, Jiqiu Wang, Weiren Liu, Yanyun Gu, Shuangshuang Yao, Jian Yang, Yifei Zhang, et al.


  • Open Access

    Serum and thyroid tissue level of let-7b and their correlation with TRAb in Graves’ disease

    by Xinxin Chen, Fengjiao Huang, Yicheng Qi, Mengxi Zhou, Qinglei Yin, Ying Peng, Yulin Zhou, Guang Ning, Shu Wang

    Abnormal microRNAs (miRNAs) were reported to be involved in the mechanism of Graves’ disease (GD). Dysregulated miRNAs may be overlapping in different cells and can be secreted to circulation. We chose miRNAs which were previously reported to be differentially expressed in peripheral blood mononuclear cells (PBMCs) in patients with GD with different disease stage, detected the expression of those miRNAs in serum, corroborated the findings in thyroid tissue, and validated the target gene in vitro to investigate the possible role of circulating miRNAs in GD. A total of 54 individuals with untreated GD, 12 individuals with GD in remission and 14 disease-free controls were enrolled. The expression of miR-142-3p, miR-154-3p, miR-431-3p, miR-590-5p, and let-7b was detected in the serum. Ten thyroid tissue samples from patients with GD and six disease-free thyroid samples were used for further validation. The potential target genes were identified and validated in vitro. miR-142-3p, miR-154-3p, miR-431-3p, miR-590-5p, and let-7b were present in serum and two of them (miR-142-3p and let-7b) were significantly increased in serum of patients with untreated GD (for serum miR-142-3p, P = 0.033, for serum let-7b, P = 0.026) and gradually decreased to normal levels in patients with GD in remission. Correlation analysis showed that let-7b level was strongly correlated with TRAb level (r = 0.305, P = 0.001). let-7b directly inhibited promyelocytic leukemia zinc finger (PLZF) expression and increased the expression of TSHR in thyroid cells in vitro. Furthermore, let-7b levels in GD thyroid tissue were found to be inversely correlated with PLZF levels (r = − 0.849, P = 0.033). Decreased PLZF and increased TSHR was validated in thyroid tissue in patients with GD. The present study confirmed that a portion of miRNAs in PBMCs were also presented and differentially expressed in serum and thyroid tissue. Upregulated in all these three compartments, let-7b may be used as a disease biomarker and therapeutic targets in patients with GD. Circulating let-7b had a strong correlation with disease severity and let-7b may participate in the production of TRAb via targeting PLZF in patients with GD.